| Literature DB >> 26739274 |
Luigi Calamari1, Annarita Ferrari2, Andrea Minuti3, Erminio Trevisi4.
Abstract
BACKGROUND: Although a metabolic profile represents a valid tool utilized in dairy herds to determine abnormalities in blood chemistry related to an increased risk of production diseases, there are no studies on application of Fourier Transform mid-infrared (FT-MIR) spectroscopy. This study assesses the potential application of FT-MIR to analyze the main blood biochemical parameters included in the metabolic profile of dairy cows. Infrared transmission spectra were acquired for 35 plasma samples (two replicates on each sample) of Italian Friesian dairy cows (14 primiparous and 21 pluriparous), all without clinical events, and at different stages of lactation, although mainly in the transition phase. Each sample was also analyzed independently using accepted reference clinical chemical methods and these results were used as calibrating values to perform predictive models by PLS method using cross validation.Entities:
Mesh:
Year: 2016 PMID: 26739274 PMCID: PMC4704406 DOI: 10.1186/s12917-015-0621-4
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Methodologies used to measure the plasma parameters with reference methods
| Parameter | Methodology | Wavelength (nm) | CVa |
|---|---|---|---|
| Glucose | Endpoint | 510 | 1.50 |
| Total cholesterol | Endpoint | 510 | 2.10 |
| NEFAb | Endpoint | 546 | 1.50 |
| BHBAc | Endpoint | 340 | 5.25 |
| Urea | Endpoint | 340 | 1.20 |
| Creatinine | Endpoint | 510 | 5.40 |
| Ca | Endpoint | 570 | 1.40 |
| Inorganig P | Endpoint | 340 | 2.00 |
| Mg | Rate | 340 | 1.40 |
| Na | ISE deviceg | 0.90 | |
| K | ISE deviceg | 1.30 | |
| Cl | ISE deviceg | 1.50 | |
| Zn | Endpoint | 546 | |
| Ceruloplasmin | Endpoint | 546 | 3.48 |
| Total protein | Endpoint | 546 | 1.20 |
| Albumin | Endpoint | 600 | 1.80 |
| Total bilirubin | Endpoint | 546 | 6.70 |
| Haptoglobin | Endpoint | 450 | 13.54 |
| ASTd | Rate | 340 | 2.10 |
| GGTe | Rate | 405 | 3.72 |
| APf | Rate | 405 | 1.70 |
aCalculared on the results obtained between runs according to the National Committee for Clinical Laboratory Standards (Document EP3-T: Guidelines for Manufacturers for Establishing
Performance Claims for Clinical Chemistry Methods, Replication Experiment
Evaluation”, Villanova, PA, 1982.)
bNon esterified fatty acids;
cβ-OH-butyric acid;
dAspartate amino transferase
eγ-glutamyl transferase
fAlkaline phosphatase
gIon selective electrodes
Descriptive statistic (35 plasma samples)
| Item | Mean | SD | Min | Max | Median | SKa | KUb |
|---|---|---|---|---|---|---|---|
| Glucose, mmol L−1 | 4.02 | 0.67 | 1.66 | 6.20 | 3.95 | −0.13 | 5.64 |
| Total cholesterol, mmol L−1 | 3.36 | 1.59 | 0.80 | 5.87 | 3.18 | 0.05 | −1.57 |
| NEFAc, mmol L−1 | 0.33 | 0.29 | 0.06 | 1.18 | 0.20 | 1.06 | 0.30 |
| NEFAc, ln(mmol L−1) | −1.52 | 0.94 | −2.83 | 0.16 | −1.61 | 0.17 | −1.49 |
| BHBAd, mmol L−1 | 0.49 | 0.13 | 0.28 | 0.85 | 0.47 | 1.00 | 0.78 |
| BHBAd, ln(mmol L−1) | −0.74 | 0.25 | −1.28 | −0.16 | −0.76 | 0.34 | 0.06 |
| Urea, mmol L−1 | 4.21 | 1.42 | 1.50 | 7.52 | 4.02 | 0.21 | −0.61 |
| Creatinine, μmol L−1 | 99.54 | 10.67 | 83.62 | 125.89 | 97.57 | 0.47 | −0.51 |
| Ca, mmol L−1 | 2.58 | 0.12 | 2.36 | 2.86 | 2.61 | 0.33 | −0.16 |
| Inorganig P, mmol L−1 | 1.81 | 0.35 | 1.19 | 2.89 | 1.74 | 1.09 | 1.36 |
| Mg, mmol L−1 | 1.02 | 0.10 | 0.57 | 1.12 | 1.04 | −2.97 | 9.99 |
| Na, mmol L−1 | 144.20 | 3.44 | 138.78 | 151.78 | 143.81 | 0.38 | −0.68 |
| K, mmol L−1 | 4.07 | 0.20 | 3.59 | 4.57 | 4.08 | −0.09 | 0.20 |
| Cl, mmol L−1 | 107.51 | 2.48 | 102.27 | 112.98 | 107.46 | −0.09 | −0.19 |
| Zn, μmol L−1 | 11.43 | 2.71 | 5.17 | 16.19 | 11.40 | −0.48 | −0.19 |
| Ceruloplasmin, μmol L−1 | 3.24 | 1.02 | 1.99 | 6.63 | 3.03 | 1.48 | 2.41 |
| Total protein, g L−1 | 76.07 | 6.27 | 63.57 | 86.89 | 77.10 | −0.35 | −0.67 |
| Albumin, g L−1 | 35.90 | 2.65 | 25.79 | 39.55 | 36.26 | −2.07 | 5.68 |
| Globulin, g L−1 | 40.05 | 6.33 | 27.99 | 52.08 | 40.61 | −0.23 | −0.78 |
| Total bilirubin, μmol L−1 | 3.98 | 4.63 | 0.29 | 22.48 | 2.14 | 2.57 | 6.98 |
| Total bilirubin, ln(μmol L−1) | 0.94 | 0.91 | −1.24 | 3.11 | 0.76 | 0.35 | 0.24 |
| Haptoglobin, g L−1 | 0.25 | 0.27 | 0.03 | 0.91 | 0.10 | 1.46 | 0.69 |
| Haptoglobin, ln(g L−1) | −1.91 | 0.98 | −3.51 | −0.09 | −2.30 | 0.60 | −0.87 |
| ASTe, U L−1 | 106.67 | 69.78 | 49.98 | 394.07 | 89.35 | 3.15 | 9.75 |
| ASTe, ln(U L−1) | 4.56 | 0.42 | 3.91 | 5.98 | 4.49 | 1.90 | 4.32 |
| GGTf, U L−1 | 28.78 | 9.66 | 16.27 | 63.94 | 26.63 | 1.50 | 3.64 |
| GGTf, ln(U L−1) | 3.32 | 0.31 | 2.79 | 4.16 | 3.28 | 0.40 | 0.20 |
| APg, U L−1 | 50.85 | 22.75 | 21.44 | 103.73 | 42.84 | 0.87 | −0.21 |
| APg, ln(U L−1) | 3.84 | 0.43 | 3.07 | 4.64 | 3.76 | 0.23 | −0.88 |
aSkewness
bKurtosis
cNon esterified fatty acids
dβ-OH-butyric acid
eAspartate amino transferase
fγ-glutamyl transferase
gAlkaline phosphatase
Calibration curves and cross validation
| Item | Extracted factorsa | R2 | RMSECVb | RERc | RPDd | Sr e | RSDr f |
|---|---|---|---|---|---|---|---|
| Glucose, mmol L−1 | 5 | 0.66 | 0.3893 | 11.7 | 1.7 | 0.1550 | 3.86 |
| Total cholesterol, mmol L−1 | 7 | 0.99 | 0.1156 | 43.8 | 13.8 | 0.0690 | 2.06 |
| NEFAg, mmol L−1 | 6 | 0.86 | 0.1094 | 10.2 | 2.7 | 0.0325 | 9.80 |
| NEFAg, ln(mmol L−1) | 5 | 0.78 | 0.4414 | 6. 8 | 2.1 | 0.1214 | 7.99 |
| BHBAh, mmol L−1 | 5 | 0.38 | 0.1012 | 5.6 | 1.3 | 0.0245 | 4.98 |
| BHBAh, ln(mmol L−1) | 7 | 0.60 | 0.1572 | 7.1 | 1.6 | 0.0669 | 9.03 |
| Urea, mmol L−1 | 6 | 0.90 | 0.4623 | 13.0 | 3.1 | 0.2454 | 5.83 |
| Creatinine, μmol L−1 | 4 | 0.60 | 6.7608 | 6.3 | 1.6 | 0.3080 | 0.31 |
| Ca, mmol L−1 | 3 | 0.60 | 0.0791 | 6.3 | 1.6 | 0.0048 | 0.19 |
| Inorganig P, mmol L−1 | 5 | 0.55 | 0.2336 | 7.3 | 1.5 | 0.0545 | 3.00 |
| Mg, mmol L−1 | 4 | 0.55 | 0.0701 | 7.8 | 1.5 | 0.0063 | 0.62 |
| Na, mmol L−1 | 4 | 0.57 | 2.2673 | 5.7 | 1.5 | 0.3289 | 0.23 |
| K, mmol L−1 | 2 | 0.10 | 0.1920 | 5.1 | 1.0 | 0.0043 | 0.11 |
| Cl, mmol L−1 | 6 | 0.70 | 1.3219 | 8.1 | 1.9 | 0.3198 | 0.30 |
| Zn, μmol L−1 | 4 | 0.49 | 1.9577 | 5.6 | 1.4 | 0.2240 | 1.96 |
| Ceruloplasmin, μmol L−1 | 3 | 0.59 | 0.6575 | 7.1 | 1.5 | 0.0705 | 2.17 |
| Total protein, g L−1 | 5 | 0.99 | 0.7452 | 31.3 | 8.4 | 0.1561 | 0.21 |
| Albumin, g L−1 | 6 | 0.96 | 0.5082 | 27.1 | 5.2 | 0.1362 | 0.38 |
| Globulin, g L−1 | 4 | 0.98 | 0.8128 | 29.6 | 7.8 | 0.2665 | 0.67 |
| Total bilirubin, μmol L−1 | 5 | 0.75 | 2.2967 | 9.7 | 2.0 | 0.6654 | 16.71 |
| Total bilirubin, ln(μmol L−1) | 3 | 0.66 | 0.5320 | 8. 2 | 1.7 | 0.0225 | 2.40 |
| Haptoglobin, g L−1 | 4 | 0.62 | 0.1678 | 5.2 | 1.6 | 0.0148 | 5.97 |
| Haptoglobin, ln(g L−1) | 4 | 0.66 | 0.5734 | 6.0 | 1.7 | 0.0494 | 2.59 |
| ASTi, U L−1 | 6 | 0.69 | 39.5398 | 8.7 | 1.8 | 9.1112 | 8.54 |
| ASTi, ln(U L−1) | 4 | 0.54 | 0.2856 | 7.2 | 1.5 | 0.0282 | 0.62 |
| GGTl, U L−1 | 4 | 0.40 | 7.5093 | 6.3 | 1.3 | 0.3565 | 1.27 |
| GGTl, ln(U L−1) | 3 | 0.42 | 0.2344 | 5.8 | 1.3 | 0.0154 | 0.46 |
| APm, U L−1 | 7 | 0.66 | 13.2962 | 6.2 | 1.7 | 8.3024 | 16.33 |
| APm, ln(U L−1) | 7 | 0.64 | 0.2614 | 6.02 | 1.6 | 0.1696 | 4.42 |
aNumber of extracted factors with the PLS procedure
bRoot mean square error of cross validation
cRange error ratio, obtained dividing the range of each variable by its standard deviation of prediction errors
dRatio of prediction to deviation, obtained dividing the standard deviation of each variable with its standard deviation of prediction errors
eRepeatability of the standard deviation
fRepeatability relative standard deviation
gNon esterified fatty acids
hβ-OH-butyric acid
iAspartate amino transferase
lγ-glutamyl transferase
mAlkaline phosphatase
Fig. 1Linear regression plots for total cholesterol. Relationship between total cholesterol concentration (mmol L−1) measured by the reference method and by FT-MIR spectrometry in plasma using mid-infrared spectra (70 observations). (R2 = 0.995; root mean square error of cross validation = 0.1156; RER = 43.8; RER is the range error ratio, and is obtained dividing the range of total cholesterol with its standard deviation of prediction errors; RPD = 13.8, where RPD is the ratio of prediction to deviation, and is obtained dividing the standard deviation of total cholesterol with its standard deviation of prediction errors)
Fig. 2Linear regression plots for total protein. Relationship between total protein concentration (g L−1) measured by the reference method and by FT-MIR spectrometry in plasma using mid-infrared spectra (70 observations). (R2 = 0.985; root mean square error of cross validation = 0.7452; RER = 31.3; RER is the range error ratio, and is obtained dividing the range of total protein by its standard deviation of prediction errors; RPD = 8.4; RPD is the ratio of prediction to deviation, and is obtained dividing the standard deviation of total protein by its standard deviation of prediction errors)